anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Poor adherence to HAART is usually associated with resistant virus. Poor adherence to HAART can have serious consequences, including limited treatment options for HIV infected individuals if they become infected with resistant HIV. The purpose of this study was to examine the effectiveness of modified directly observed therapy (mDOT) and compare it with the effectiveness of self-administered therapy (non-mDOT) in HIV infected individuals with first virologic failure on an NNRTI-based HAART regimen who were starting a PI-based HAART regimen at study entry.

mDOT was defined in this study as the daily observation of lopinavir/ritonavir (LPV/r) being taken on a regular basis. Observation consisted of an mDOT partner being present at the time the study participant took the observed dose. Half of the participants in this study were required to choose an mDOT partner to supervise adherence for the first 24 weeks of the study. Each mDOT partner completed the study-administered mDOT training program and was required to record all observed doses in an mDOT diary log. All participants and partners received health education through the study. Adherence was measured using Medication Event Monitoring System (MEMS) caps and self-report questionnaires.

This study lasted 52 weeks. Per protocol, participants were to be stratified according to their screening viral load and the proposed study treatment. The study treatment each participant received was based on their treatment history. At entry, participants were to start one of the two PI-based HAART regimens, either FTC/Tenofovir Disoproxil Fumarate (TDF) 200/300 mg once daily (QD) and Lopinavir/Ritonavir (LPV/RTV) 400/100 mg twice a day (BID) or TDF 300 mg QD and zidovudine (ZDV) 300 mg BID and LPV/RTV 400/100 mg BID. mDOT was used for the first 24 weeks of the study, followed by self-administration of study medications from week 25 to week 52. ZDV was not provided by the study. All enrolled participants except one who did not start study regimen initiated FTC/TDF and LPV/rtv after randomization. No participants started ZDV containing regimen on study. Thus, participants in this study were stratified by screening HIV-1 RNA only.

There were eight visits during the study. Medical and medication history, blood collection, and clinical assessment were required at all visits. A quality of life questionnaire and an adherence tools assessment were collected at most visits. For the mDOT arm, medication diary logs and mDOT partner monitoring were reviewed at most visits. An mDOT exit questionnaire and exit interview were required at the end of the study.
The invention relates to a traditional Chinese medicine pill capable of being used for treating hypoadrenocorticism disease. Traditional Chinese medicine holds that soothing the liver, tonifying the kidney, clearing away heat and eliminating, dampness, strengthening body and strengthening the body resistance are critical ways for treating hypoadrenocorticism. Thus, the pill for treating hypoadrenocorticism is prepared from the main components including 25% of tarragon, 10% of malaytea scurfpea, 10% of deerhorn gelatin, 10% of rhodiola sachalinensis, 10% of herba epimedii, 5% of scutellaria baicalensis, 5% of codonopsitis pilosula, 5% of astragalus mongholicus, 5% of loranthus parasiticus, 5% of barbary wolfberry fruit, 5% of rehmannia glutinosa and 5% of glossy privet fruit, and is prepared by finely grinding the 12 medicines according to proportion, and evenly mixing the ground medicines to prepare pills or tablets. The pill is orally taken three times every day, 1.5-2g of the pill is taken by warm boiled water after meal every time, and the pill is continuously taken for 7-14 days. In the period of taking the pill for treating hypoadrenocorticism, wine and spicy food are forbidden, a small amount of meat and plenty of vegetables can be eaten, and more movement is needed. After the pill is taken, the effect is obvious, the symptom is alleviated, and the quality of life is obviously improved.
Irritable bowel syndrome (IBS) is a prevalent functional bowel disorder in which recurrent abdominal pain is associated with defecation and altered bowel habits. Although the pathophysiology is incompletely understood, it is generally regarded as a multifactorial disorder involving host factors such as low-grade immune activation, altered intestinal barrier function and defense. Environmental factors, including diet, are also suggested to play a role. Dairy products such as cow's milk are widely produced and an important component of the human diet. Cow's milk is composed of various macronutrients, micronutrients and water. Beta-casein is a major protein component of cow's milk; most cows produce a mixture of A1 and A2 beta-casein (conventional milk), whereas some cows produce only A2 beta-casein (A2 milk). It has been suggested that specific components in cow's milk, such as A1 beta-casein, may trigger gastrointestinal symptoms after intake.

The purpose of this randomized, double-blind, cross-over study performed in Maastricht University Medical Center (MUMC+) is to explore the acute and mid-terms effects of A2 milk versus conventional milk on gastrointestinal symptoms and immune and defense markers in separate groups of patient with constipation-predominant IBS and in patients with diarrhea-predominant IBS.
Four out of five youth in the juvenile justice system show evidence of being under the influence during their offenses, and over half test positive for substances at the time of their arrest. Further, 92% of arrested juveniles who tested positive for drugs tested positive for marijuana. Although some treatment programs for juvenile offenders exist, most have focused on detained and incarcerated juveniles, who only represent one third of arrested youth. As a result, little is known about how to improve the continuum of care for the remaining two-thirds of this population, which consists of court involved but non-incarcerated youth (CINI). Court recommendations and referrals for CINI have mostly relied on outside community-based services, thus decreasing the likelihood CINI youth and their families will take the additional steps to seek intervention. Given that motivational interventions (MI) are brief, relatively easy to implement and have a greater reach than typical substance use treatment programs, researchers have recently directed their focus to interactive, computer-delivered MI protocols to further increase their reach as well as facilitate their implementation. Online interventions can be delivered at a lower cost, with less demand on staff time for training, and increased protocol fidelity, portability, and ease of use. While counselor-delivered MIs for adolescent substance use have been tested fairly widely, only a few studies have been published on the efficacy of computer-assisted MIs. Further, little research has focused on the efficacy of such interventions with marijuana using adolescents in general, and more specifically with CINI adolescents. In addition, combining such interventions for adolescents with brief parenting interventions is important but yet rarely implemented. Therefore, this application proposes to examine the feasibility and acceptability of integrating a computer-assisted,, brief intervention protocol into the juvenile intake procedures at the Rhode Island Family Court (RIFC) for marijuana using adolescents and their parents. Following an open trial of the brief protocol, , 80 adolescents who screen positive for marijuana use at juvenile intake will be recruited from the RIFC and randomly assigned to one of two conditions: 1) a computer-assisted adolescent MI plus an online parenting program ; or 2) usual care. Outcomes will be examined at 3 and 6-month follow-ups. This small trial will provide some initial evidence regarding utility of this protocol with CINI youth and whether a larger, fully powered trial is indicated in the future.
Consumption of a portion of Piping Rock Potassium Iodide supplements equivalent to 200 µg of iodine (1.3 tablets) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
Patients with advanced urothelial cancer will be treated with platinum-based chemotherapy. After chemotherapy, an imaging study will be performed to determine cancer response. If there is no disease progression, patients will be eligible for this study. After informed consent is obtained, patients are enrolled. The treatment include immunotherapy avelumab as the standard of care plus a study medication copanlisib. Both medications are administrated through intravenous infusion. Avelumab wil be given once every two weeks while copanlisib will be administrated on Day 1, 8 and 15 of every 4-week cycle. Patient will be followed up for disease progression.
NEW MATERIAL:Compounds represented by formula I (X is H or OR; R is H or straight or branched chain lower alkyl). EXAMPLE:1,3,8-Paramenthatrien-7-al(dehydroperillaldehyde). USE:A perfume showing a floral-like, cumin-like, wine-like, honey-like fragrance, useful as a perfume material, especially as a perfume material capable of improving faults of a conventional honey flavor such as offensiveness and, in addition thereto, useful for emphasizing flesh feeling and for improving natural-like flavor when added to a perfume composition. PREPARATION:Perillaldehyde of formula 1 is converted to its enol acetate using isopropenyl acetate followed by bromination with bromosuccinimide. The resultant compound is hydrolyzed to obtain a compound of formula 3 and the hydrolyzed compound is then subjected to dehydrobromination in dimethylformamide using potassium acetate to obtain a compound of formula 4 in formula I. The obtained compound is oxidized by using silver nitrate, thus obtaining the objective compound of formula 5 in formula I.
Regular intestinal lavage with normal saline twice per day, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. The intervention will be applied at a maximum of 2 weeks from birth.
OBJECTIVE: Acute treatment in mild stroke patients with acute anterior circulation large vessel occlusion/stenosis (AACLVO/S) had limited evidence. Hemodynamic play an important role in neurological deterioration. We aimed to investigate predictor value of hemodynamic assessment for clinical outcome predicting and guiding individual therapeutic decisions in those patients.
METHODS: We retrospectively analyze the stroke database in our stroke center. We recruited patients with mild stroke, defined by National Institutes of Health Stroke Scale (NIHSS) score ≤ 5, caused by AACLVO/S treated with just medical management (MT). They all received cerebral autoregulation (CA) assessments within 72 h after stroke onset. The primary end point was clinical outcome at 90-day after stroke.
RESULTS: Logistic regression analysis showed that bilateral higher baseline phase difference (PD) were independent variables related to favorable 90-day outcome, (OR 0.963, 95% CI 0.936-0.991, p = 0.040; OR 0.943, 95% CI 0.970-0.997; p = 0.008, respectively). The optimal cutoff value of bilateral PD was > 34.97º and > 14.29º respectively.
CONCLUSION: CA evaluation can provide hemodynamic status in mild stroke patients with AACLVO/S.
The invention discloses a recombination recin toxin B chain truncated protein and an expressing method and application thereof, and relates to the field of bioengineering. The technical problems that an existing recombination recin toxin B chain protein is low in renaturation, poor in renaturation protein stability and the like are solved. The nucleotide sequence of the recombination recin toxin B chain truncated protein is shown in the SEQ ID NO:1 in a sequence table. The amino acid sequence of the recombination recin toxin B chain truncated protein is shown in the SEQ ID NO:2 in the sequence table. The expressing method of the recombination recin toxin B chain truncated protein comprises the step of expressing the recombination recin toxin B chain truncated protein through an escherichia coli expression system. According to the recombination recin toxin B chain truncated protein, the renaturation rate is improved, the stability is enhanced, the immunogenicity is good, the vaccine immunity effect is enhanced, the vaccine consumption is lowered, and the recombination recin toxin B chain truncated protein can be used as adjuvants of various vaccines such as inactivated vaccines, activity reduction vaccines, split vaccines, DNA vaccines, recombinant vaccines, subunit vaccines and polypeptide protein vaccines.
The present invention relates to a biphenyl dimethyl dicarboxylate orally disintegrating tablet and a preparation process thereof. The biphenyl dimethyl dicarboxylate orally disintegrating tablet can be used for treating chronic unresolved hepatitis accompanied by abnormal increase or chemical-caused increase of alanine aminotransferase (ALT). The present invention aims at making up for the preparation insufficiency of existing biphenyl dimethyl dicarboxylate preparation and providing a biphenyl dimethyl dicarboxylate orally disintegrating tablet and a preparation process thereof for all patients and medical workers; the biphenyl dimethyl dicarboxylate orally disintegrating tablet has the advantages of convenient use and rapid absorption and effect-taking. Biphenyl dimethyl dicarboxylate is used as raw material; using filling agent, disintegrating agent, corrigent, flow aid, lubricating agent, etc. as auxiliary materials; filling agents, disintegrating agents, corrigents, flow aid, lubricating agents, etc. are used as auxiliary materials; adhesives or coating materials can also be used according to different situations; appropriate quantity of effervescent agents can be added on specific situation; the orally disintegrating tablet is prepared by a specific preparation method and obtained after tabletting by tabletting machines. The orally disintegrating tablet of the present invention has the characteristics of good friability, rapid disintegration, good taste, no gravel feel, no need of specific production condition, low production cost, convenient carry, storage, transportation and use, etc.; most of all, the orally disintegrating tablet can be taken without water and takes effect quickly, and therefore, the present invention improves the patient's compliance and enhances the curative effect of the medicine.
PURPOSE: The management of ovarian torsion in pediatric patients has evolved over time. Ovarian salvage is currently recommended given concerns for fertility preservation and the low likelihood of malignancy. Studies have shown that the incidence of oophorectomy is higher amongst pediatric surgeons in comparison to gynecologists. Using a national database, this study examined how the surgical management of ovarian torsion has evolved.
METHODS: Children with a discharge diagnosis of ovarian torsion (ICD-9 code 620.5, ICD-10 code N835X) and procedure codes for oophorectomy (CCS code 119) were identified within the KID database from 2003, 2006, 2009, 2012, 2016, and 2019. Diagnosis of ovarian pathology was based upon ICD-9 and ICD-10 codes at the time of discharge.
RESULTS: A total of 7008 patients, ages 1-20, had a discharge diagnosis of ovarian torsion. Of those patients, 2,597 (37.1%) were diagnosed with an ovarian cyst, 1560 (22.2%) were diagnosed with a benign ovarian neoplasm, and 30 (0.4%) were diagnosed with a malignant neoplasm. There was a decreased risk of oophorectomy in urban-teaching versus rural hospitals (OR: 0.64, p < 0.001). The rate of oophorectomy has decreased overtime. However, patients with benign or malignant neoplasms were more likely to undergo oophorectomy than those without a diagnosis (OR: 2.03, p < 0.001; 4.82, p < 0.001).
CONCLUSION: The rate of oophorectomy amongst children with ovarian torsion has decreased over time. Yet, despite improvements, oophorectomy is common amongst patients with benign ovarian neoplasms and those treated at rural hospitals. Continued education is needed to optimize patient care in all clinical scenarios.
LEVEL OF EVIDENCE: IV.
The present invention providesA preparation method and application of tegaserod water-soluble organic acid salt are provided. Specifically disclosed is a water-soluble organic acid salt of a compound represented by the general structural formula (I). The organic salt can be used as PI3K/Akt/mTOR and JAK-STAT3 signal pathway inhibitor and immunomodulator, and is used for developing medicaments for treating tumors and inflammations. In the organic acid salt of tegaserod, the solubility of tegaserod D-pyroglutamate in water is more than 600mg/mL, which is improved by more than 3000 times than that of maleate. Therefore, the method has obvious advantages in the aspects of pharmacokinetic behaviors in a medicine body, development of new dosage forms of medicines and the like, and can be used for improving the preparation process and developing new dosage forms and has practicability. In the research of the antitumor activity in mice, tegaserod D-pyroglutamate has obvious inhibitory activity to prostate cancer and melanoma, wherein the inhibitory activity to the growth of melanoma B16F10 reaches 50.6%.
An objective and validated index of nausea and vomiting such as the Pregnancy-Unique Quantification of Emesis (PUQE) and HyperEmesis Level Prediction (HELP) tools can be used to classify the severity of NVP and HG. [Grade C] Ketonuria is not an indicator of dehydration and should not be used to assess severity. [Grade A] There are safety and efficacy data for first line antiemetics such as anti (H1) histamines, phenothiazines and doxylamine/pyridoxine (Xonvea®) and they should be prescribed initially when required for NVP and HG (Appendix III). [Grade A] There is evidence that ondansetron is safe and effective. Its use as a second line antiemetic should not be discouraged if first line antiemetics are ineffective. Women can be reassured regarding a very small increase in the absolute risk of orofacial clefting with ondansetron use in the first trimester, which should be balanced with the risks of poorly managed HG. [Grade B] Metoclopramide is safe and effective and can be used alone or in combination with other antiemetics. [Grade B] Because of the risk of extrapyramidal effects metoclopramide should be used as second-line therapy. Intravenous doses should be administered by slow bolus injection over at least 3 minutes to help minimise these. [Grade C] Women should be asked about previous adverse reactions to antiemetic therapies. If adverse reactions occur, there should be prompt cessation of the medications. [GPP] Normal saline (0.9% NaCl) with additional potassium chloride in each bag, with administration guided by daily monitoring of electrolytes, is the most appropriate intravenous hydration. [Grade C] Combinations of different drugs should be used in women who do not respond to a single antiemetic. Suggested antiemetics for UK use are given in Appendix III. [GPP] Thiamine supplementation (either oral 100 mg tds or intravenous as part of vitamin B complex (Pabrinex®)) should be given to all women admitted with vomiting, or severely reduced dietary intake, especially before administration of dextrose or parenteral nutrition. [Grade D] All therapeutic measures should have been tried before considering termination of pregnancy. [Grade C].
The investigators working hypothesis is that RNase L and RLI contribute to chronic inflammation regulation and to insulin response through TLR 4 pathway regulation in obesity. The investigators main purpose is to compare innate immunity activation pathway between insulin sensitive, insulin resistant obese patients and control patients. Insulin sensitive and insulin resistant obese patients will be distinguish thanks to the HOMA ir index. The investigators second objectives are to evaluate if the degree of inflammation in adipose tissue and squeletal muscle is correlated to insulin sensitivity measured by hyperinsulinemic euglycemic clamp and to characterise inflammatory pathway and regulation pathway. A special focus will be given to the leukotrienes and their potential role in insulin resistance pathogenesis. The investigators will have two approaches:- characterisation of subjects with normal weight, of obese insulin sensitive and obese insulin resistant through a metabolic evaluation, an inflammatory characterisation and a measure of insulin sensitivity at the systemic level, in adipose tissue and in squeletal muscle.- an in vitron approach with human myoblast and adipocytes culture, extracted from the investigators patients: characterisation of inflammation, innate immunity.
Fibromyalgia (FM) is a common syndrome characterized by widespread pain and at least 11/18 painful tender points (American College of Rheumatology). Fibromyalgia syndrome (FMS) is a rheumatic condition of increasing prevalence worldwide) approximately 2-7% of the populations are affected. Some of the symptoms associated with fibromyalgia is sleep disturbance, dizziness, headache, fatigue, depression/tension, pain, cognitive disorder, irritable bowel syndrome, and different somatic symptoms. These factors negatively influence physical and emotional characteristics and decrease the quality of life. Fatigue and dyspnea are the significant signs and symptoms of fibromyalgia, which can be related to respiratory system changes. Major affected areas in fibromyalgia include breathing mechanics, the upper trapezius muscle, the cervical muscle mass, the scalene, Sternocleidomastoid, and the area around the second rib and all the paravertebral muscle mass. These regions are coordinated with the tender points placed in the upper half body of patients with FM. Fibromyalgia patients, without a doubt, exhaust and come to be fatigue due to the dyspnea. It is widespread among females; however, it can additionally affect both men and teenagers. Many pharmacological therapies were being used to treat FM with uncertain consequences, and steadily growing small doses are usually recommended to maximize efficacy. Among non pharmacological management including exercise is typically endorsed in the management of patients with fibromyalgia. Regular workout is an essential keystone of fibromyalgia management. Aerobic workout interventions have shown reduced ache, depression, and fatigue, improving health-related quality of life (HRQOL). Related literature includes meta-analysis regarding the exercise effects (endurance, aerobic, or mixed aerobic and strength workout) on worldwide welfare in people with fibromyalgia. Breathing issues tend to intensify FM symptoms. The FM patients exhaust quickly, and dyspnea causes fatigue related to respiratory muscle weakness, mainly diaphragmatic deficiency, that can decrease the physical condition and capability inside the daily activities. Breathing exercises have been proven to be useful in decreasing symptoms of FM. MET is the osteopathic manipulation strategies of the tender tissues that evolved to recover the musculoskeletal system's function and decrease pain. Both these techniques have proven effects for reduction of symptoms in FM patients. This study is intended to compare the effects of both in order to find out the technique that can effectively improve the functional outcomes in patients with fibromyalgia.